Peptide library / Heart & blood / Icatibant
Icatibant
A ten amino acid bradykinin blocker for attacks of hereditary angioedema.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Acute attacks of hereditary angioedemaFDA approved
How it is thought to work
Icatibant blocks the bradykinin B2 receptor, which drives the swelling in hereditary angioedema.
What the evidence shows
Phase 3 trials showed faster symptom relief than placebo, and patients can self-inject.
Safety and unknowns
Injection site pain and redness are very common.
Regulatory status
FDA-approved as Firazyr in 2011.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Heart & blood
Motixafortide
FDA-approvedA CXCR4 blocker that pushes stem cells into the blood for collection before transplant.
Nesiritide
FDA-approvedA recombinant B-type natriuretic peptide once widely used in acute heart failure.
Eptifibatide
FDA-approvedA cyclic peptide platelet blocker modeled on rattlesnake venom, used in acute coronary syndromes.
General information, not medical advice. Do not buy or inject unregulated peptides.